Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement
Segments

Common Size IS
Op Efficiency
Credit Analysis

Bellerophon Therapeutics, Inc. (BLPH)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
  Older >>
In millions, except per share itemsDec-31-22Dec-31-21Dec-31-20Dec-31-19Dec-31-18Dec-31-17Dec-31-16Dec-31-15
   10-K10-K10-K10-K10-K10-K10-K10-K/A
Revenues:          
Licensing revenue         33.4
            Licensing revenue growth        -100.0% 
Operating expenses:          
Research and development  16.413.017.911.020.317.916.7 
General and administrative  6.07.18.46.47.66.77.114.9
    Total operating expenses  22.420.226.317.527.924.623.848.2
Loss from operations  -22.4-20.2-26.3-17.5-27.9-24.6-23.8-46.6
Interest and other income, net  0.10.0-0.30.40.4   
    Pre-tax loss  -22.2-19.6-26.9-15.1-2.6-54.8-24.3 
Income tax benefit  2.41.82.11.85.4 0.4 
    Net loss and comprehensive loss  -19.8-17.8-24.7-13.32.8-54.8-23.8-46.5
   
Weighted average shares outstanding:          
Basic (in shares)  9.69.57.84.53.82.615.112.3
Diluted (in shares)  9.69.57.84.54.32.615.112.3
   
Net loss per share:          
Basic (in dollars per share)  ($2.08)($1.87)($3.17)($2.95)$0.73($21.11)($1.58)($3.79)
Diluted (in dollars per share)  ($2.08)($1.87)($3.17)($2.95)($5.07)($21.11)($1.58)($3.79)

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy